PRP and Nanofat: When Can the Combination Be an ATMP?
Regulatory assessment · EMA/CAT 2026

PRP plus nanofat: When can the combination qualify as an ATMP?

In 2026, the EMA Committee for Advanced Therapies classified one specific PRP–nanofat product as a tissue-engineered product. What that means for other uses—and what it does not mean.

09.11.2026For healthcare professionalsScientific article and source review
Read the original CAT minutes ↗
Regulatory assessment concerns the finished product
PRPfrom blood
+
Nanofatfrom adipose tissue
↓
Specific combinationwith defined processing and intended use
Regulatory questions:
CompositionDegree of manipulationEssential functionIntended use

Conceptual overview only; not a classification or legal clearance.

01

Why regulation is complex

PRP and nanofat originate from different autologous tissues. Combining them does not create a product that can be classified solely by calling it autologous or mechanically processed.

The composition of the final preparation, processing effects and its intended biological function can all matter. The CAT decision of June 2026 illustrates why superficially similar preparations may be subject to different regulatory assessments. [B1] [B2]

02

What is PRP?

Platelet-rich plasma (PRP) is plasma derived from blood, generally with a higher platelet concentration than the starting blood. The term does not specify a uniform product: platelet and leukocyte counts and other blood components vary with the preparation method.

A systematic review found that only 44 of 132 clinical PRP studies characterised the PRP composition, while only 23 reported the leukocyte content. This limits comparisons between clinical findings. [S3]

In Germany, preparation and use of PRP may raise questions under medicinal-product and blood-product law. Classification depends on the product and its use. The CAT explicitly left the regulatory status of PRP used alone unresolved. [B1] [B5]

03

What is nanofat?

Nanofat usually describes mechanically processed autologous adipose tissue. Emulsification, repeated passage and filtration methods vary, influencing the cells, extracellular matrix and tissue fragments retained.

An early laboratory characterisation found no viable adipocytes in the particular nanofat sample examined, but reported stromal and CD34-positive cells. This does not establish the composition of all nanofat preparations. [S1]

Mechanically processed nanofat, enzymatically isolated stromal vascular fraction (SVF) and culture-expanded cells are not interchangeable biological or regulatory concepts. [S2]

Figure 1Three adipose-derived product concepts compared

Mechanical nanofat

Mechanical tissue processing

Starting material
Autologous adipose tissue (lipoaspirate)
Processing
Mechanical emulsification, passage and filtration, without enzymes
Final preparation
Tissue fragments, matrix and stromal cells; the particular preparation investigated had no viable adipocytes
Regulatory question
Annex I processes are generally not substantial manipulation; intended function still requires assessment. [B2]

Enzymatically obtained SVF

Enzymatic cell dissociation

Starting material
Autologous adipose tissue
Processing
Enzymatic digestion, e.g. with collagenase, followed by separation
Final preparation
Heterogeneous cell fraction without the original tissue architecture, containing several cell populations
Regulatory question
Enzymatic tissue dissociation may constitute substantial manipulation. [B3]

Cultured and expanded cells

Cell culture and expansion

Starting material
Cells isolated from SVF
Processing
Culture and expansion over multiple passages
Final preparation
A selected population of adherent stromal cells (ASCs)
Regulatory question
Expansion in culture is a typical example of substantial manipulation. [B3]

Schematic comparison only. Processing methods and final preparations may vary; no automatic legal classification follows.

04

Why combine PRP and nanofat?

The proposed rationale for combining PRP and nanofat is that platelets and their mediators may contribute different biological signals from stromal cells and matrix components in processed adipose tissue. This is a research hypothesis, not proof of synergy.

Whether any specific combination outperforms either component requires adequately controlled studies with fully characterised preparations and indication-specific outcomes. Laboratory markers alone cannot establish clinical tissue regeneration. [S5] [S8]

05

What did the CAT decide in 2026?

At its meeting of 17–19 June 2026, the CAT considered autologous PRP combined with mechanically processed autologous adipose tissue (nanofat) for refractory olfactory dysfunction. The adopted report classified this specific product as a tissue-engineered product under Article 2(1) of Regulation (EC) No 1394/2007. [B1]

Following comments from the European Commission, the CAT explicitly noted that this finding does not prejudge the regulatory status of autologous PRP used on its own. [B1]

Classification under Article 17 is scientific advice on the submitted product, not a marketing authorisation, a clinical efficacy finding or a recommendation to treat patients. The public minutes do not include all the product-specific reasons for the classification. [B1] [B10]

Figure 2Article 17 classification pathway: PRP plus nanofat example
  1. Date not publishedClassification request

    The applicant submits information on the product and intended use; the procedure is voluntary. [B10]

  2. 60-day periodAssessment and consultation

    The CAT issues its scientific recommendation after consulting the European Commission, within the statutory period following receipt. [B2]

  3. 17–19 June 2026CAT meeting

    The report was adopted: the submitted product met the TEP definition; the status of PRP alone was expressly reserved. [B1]

  4. 15 July 2026Minutes dated

    EMA/CAT/194644/2026, section 4.4.1. The minutes do not contain the complete classification rationale. [B1]

  5. OngoingClassification summaries

    The EMA publishes summaries of classification recommendations. [B10]

FindingScientific classification of the submitted product as a TEP.
ScopeThe specific product and intended use described to the CAT.
Not establishedNo marketing authorisation, efficacy proof or treatment recommendation.
06

What are ATMPs and tissue-engineered products?

Advanced therapy medicinal products (ATMPs) include gene therapy medicinal products, somatic cell therapy medicinal products and tissue-engineered products (TEPs). A TEP comprises engineered cells or tissues and is presented or used to regenerate, repair or replace human tissue. [B2]

Under Article 2(1)(c), cells or tissues may be engineered if relevant properties are substantially manipulated, OR if they are not intended to perform the same essential function in the recipient as in the donor. These are alternative criteria, not cumulative requirements. [B2] [B3]

Autologous origin does not by itself exclude ATMP classification. Under the Regulation, a product comprising both autologous and allogeneic cells or tissues is considered allogeneic. [B2]

07

When might the combination qualify as an ATMP?

Mechanical processing does not, by itself, rule out a TEP. Annex I lists cutting, grinding, centrifugation, cell separation and filtration among manipulations not considered substantial; nevertheless a different intended essential function can be decisive. [B2] [B3]

Assessment requires the actual cell and tissue constituents, effects of the process, essential function at the intended site and the exact intended use. Neither a procedure name nor a CE mark on processing equipment settles the product classification.

Enzymatic dissociation that disrupts tissue architecture can constitute substantial manipulation, but the use of an enzyme alone does not automatically establish the status of every final product. [B3]

Figure 3Explore Article 2 criteria (illustrative, not a legal decision)

The questions show how some legal criteria relate. They cannot classify an individual product.

Question 1

Does the finished product contain human cells or tissues?

Both viable and non-viable components require appropriate consideration. [B2]

Question 2

Were relevant properties substantially manipulated?

Annex I identifies certain operations that are not substantial; culture expansion or some forms of enzymatic dissociation may be substantial. [B2] [B3]

Question 3

Will cells or tissues perform the same essential function in the recipient as in the donor?

A different essential function is an alternative route to engineered status. [B2]

Question 4

Is the product presented or used to regenerate, repair or replace human tissue?

The intended use also matters to the TEP definition. [B2]

Additional check

Does the product contain exclusively non-viable cells or tissues?

An additional statutory distinction applies to exclusively non-viable cells or tissues. [B2]

Assessment note

The TEP definition may not apply

Without cells or tissues the TEP definition is not met, although other medicinal-product or device rules may remain relevant.

Assessment note

Neither engineered criterion appears to be met

This is not legal clearance; the function assessment itself requires expert judgement and other rules may apply.

Assessment note

Some TEP characteristics may be present

A product-specific assessment is needed. Article 17 advice or dialogue with competent authorities may help; the full CAT reasoning is not in the public minutes.

Assessment note

The stated TEP purpose is not present

Other categories, including somatic cell therapy products, may need to be considered depending on the intended mechanism.

Assessment note

A special exclusion may be relevant

With exclusively non-viable components, the main pharmacological, immunological or metabolic action must be considered. This is not general regulatory freedom.

Simplified educational pathway only. It is not an ATMP classification, legal advice or a substitute for review by competent authorities.

08

Why is no blanket classification possible?

Changes to processing, constituents, function or indication can alter the regulatory assessment. The table lists issues to evaluate—not binding classifications of other products. [B1] [B2]

ScenarioPossible regulatory relevanceWhat must not be inferred
PRP aloneMedicinal- and blood-product rules may apply depending on the product and intended use.Neither blanket ATMP status nor general exemption.
Mechanically processed nanofat aloneManipulation and essential function can alter the assessment.Mechanical processing does not guarantee it is outside ATMP rules.
PRP plus nanofatOne product for refractory olfactory dysfunction was classified as a TEP in 2026.No automatic transfer to different preparations.
Enzymatically obtained cell fractionsDissociation may be relevant to substantial manipulation.Not every enzyme-derived fraction has the same status or authorisation.
PRP plus nanofat for a different purposeChanges in intended function or indication may alter classification.The CAT finding cannot simply be extended to aesthetics or other uses.

The separate legal term “combined ATMP” requires, among other conditions, an integral medical-device component. Mixing PRP with nanofat is not automatically a combined ATMP. [B2]

Being outside the ATMP category also does not automatically make a preparation a medical device or merely a medical procedure. Other rules governing medicinal products, blood and tissues may apply. [B5] [B11]

09

State of clinical evidence

Biological plausibility, clinical efficacy, safety, standardisation and regulatory classification must be assessed separately. No peer-reviewed human study of the specific PRP–nanofat combination for refractory olfactory dysfunction was identified in the underlying research. A PRP-only trial does not answer that question. [S7]

Figure 4Evidence map: what do the cited studies actually examine?
Study or review includedNo combination study identifiedNot assessed here
  • Olfaction · PRP only. Duffy 2024 investigated PRP alone; not the combination. [S7]
  • Not assessed. This matrix summarises a selected bibliography, not all worldwide publications.
  • Olfaction · combination. No peer-reviewed human study of the CAT-indicated combination was identified; classification does not assess clinical outcomes. [B1]
  • Scar reviews. The reviews address heterogeneous nanofat approaches and in some cases combinations; they do not establish an independent general PRP benefit. [S6] [S9]
  • Burn scars. Bano 2025 reports n=64, but the significance statements conflict with its table and baseline groups differ. [S5]
  • Striae. La Padula reports histological findings, with inconsistent participant numbers across sections; conclusions are limited. [S8]

Additional evidence outside the matrix: lipofilling plus PRP in vulvar lichen sclerosus (Gutierrez-Ontalvilla et al. 2022) is not automatically mechanical nanofat. [S4]

La Padula et al.2025 · striae albae

A randomised single-blind study reports histological findings; the publication gives inconsistent participant counts. Short-term markers do not prove long-term clinical benefit. [S8]

Bano et al.2025 · burn scars

64 participants; the six-month table reports p=0.030 despite a nonsignificant conclusion. Groups also differed at baseline (p=0.045). [S5]

Kuo et al.2026 · systematic review

Five studies, 108 people. Certainty was low for short-term and very low for several longer-term scar outcomes. Not evidence for PRP–nanofat combinations. [S9]

Study limitations include small samples, heterogeneity of preparation, uncertain cell composition, insufficient platelet and leukocyte reporting, short follow-up and concomitant treatments. A review covering twelve heterogeneous nanofat studies does not establish an independent PRP benefit. [S3] [S6]

For safety, short follow-up and incomplete adverse-event reporting cannot exclude uncommon risks. Sampling, processing and administration involve different risk profiles.

Studies of PRP plus nanofat in other indications cannot be transferred directly to olfactory dysfunction. The CAT classification does not assess safety or efficacy. [B1]

A paper on nanofat and additional procedures that was subsequently retracted was excluded as evidence of efficacy. [S10]

10

What healthcare facilities should consider

A meaningful regulatory review requires a clear description of the finished product, preparation steps, cells and tissues, intended biological function and clinical purpose. Place of preparation and the professional status of the clinician do not themselves resolve classification.

The hospital exemption under Article 3(7) of Directive 2001/83/EC and section 4b AMG is subject to cumulative conditions, including non-routine, patient-specific preparation, quality standards, an individual medical prescription and use in a specialised healthcare facility under a physician’s responsibility. The PEI explains that such a facility can, in certain circumstances, also be a specialised medical practice. [B4] [B6] [B9]

In Germany, section 4b(3) AMG specifically addresses authorisation for supply to others; preparation, personal application and supply must be considered separately. Section 20d AMG contains a limited exception to certain permit requirements for specified physician activities with tissues; it is not a general ATMP exemption. [B6] [B7]

11

Conclusion

In 2026 the CAT classified one specific autologous PRP–nanofat product for refractory olfactory dysfunction as a tissue-engineered product. This was not an authorisation and it is not a rule for all combinations. [B1]

The available clinical evidence is too heterogeneous to support a general therapeutic benefit from adding PRP to nanofat. Regulatory assessment and evaluation of clinical outcomes remain separate questions.

12

Frequently asked questions

Is PRP plus nanofat always an ATMP?

No. Product composition, manipulation, essential function and intended use require a case-specific assessment. [B1] [B2]

Did the EMA authorise PRP plus nanofat in 2026?

No. The CAT issued a scientific classification for one submitted product, not marketing authorisation. [B1]

Does the decision classify PRP alone as an ATMP?

No. The minutes expressly reserve the regulatory status of autologous PRP used alone. [B1]

Is mechanically processed nanofat always exempt?

No. Even non-substantially manipulated tissue may be relevant if its intended essential function changes. [B2]

Is enzymatic SVF the same as nanofat?

No. They differ in processing, composition and potentially regulatory classification. [B3] [S2]

Does CAT classification prove efficacy or safety?

No. Efficacy and safety need separate indication-specific clinical evidence. [B10]

Does use in a practice automatically qualify for hospital exemption?

No. Applicable cumulative conditions still need to be met; production, personal use and supply must be examined separately. [B6] [B9]

Sources and references

Primary regulatory sources and scientific studies are listed separately. Dynamic authority pages reviewed in November 2026.

Regulatory and legal sources

  1. B1EMA / Committee for Advanced Therapies.

    Minutes of the meeting on 17–19 June 2026. 15.07.2026. EMA/CAT/194644/2026, section 4.4.1, p. 11.

    Open original source ↗
  2. B2European Parliament and Council.

    Regulation (EC) No 1394/2007 on advanced therapy medicinal products. 13.11.2007; consolidated 26.07.2019. Arts 2, 17; Annex I.

    Open original source ↗
  3. B3EMA / Committee for Advanced Therapies.

    Reflection paper on classification of advanced therapy medicinal products. 21.05.2015; adopted 22.05.2015. EMA/CAT/600280/2010 Rev. 1.

    Open original source ↗
  4. B4European Parliament and Council.

    Directive 2001/83/EC on the Community code relating to medicinal products for human use. 06.11.2001. Art. 3(7); Annex I, Part IV.

    Open original source ↗
  5. B5Federal Republic of Germany.

    Arzneimittelgesetz (AMG) – § 4, Begriffsbestimmungen. current legal text. German statute.

    Open original source ↗
  6. B6Federal Republic of Germany.

    Arzneimittelgesetz (AMG) – § 4b, Sondervorschriften für Arzneimittel für neuartige Therapien. current legal text. German statute.

    Open original source ↗
  7. B7Federal Republic of Germany.

    Arzneimittelgesetz (AMG) – § 20d, Ausnahmen von der Erlaubnispflicht. current legal text. German statute.

    Open original source ↗
  8. B8Federal Republic of Germany.

    Arzneimittelgesetz (AMG) – § 77, Zuständige Bundesoberbehörden. current legal text. German statute.

    Open original source ↗
  9. B9Paul-Ehrlich-Institut.

    FAQ – Arzneimittel für neuartige Therapien (ATMP). updated 03.04.2025. authority guidance.

    Open original source ↗
  10. B10European Medicines Agency.

    Advanced therapy classification. online guidance. Article 17 procedure.

    Open original source ↗
  11. B11European Parliament and Council.

    Regulation (EU) 2017/745 on medical devices. 05.04.2017. Art. 1.

    Open original source ↗

Original studies and reviews

  1. S1Tonnard P et al..

    Nanofat Grafting: Basic Research and Clinical Applications. 2013. Plastic and Reconstructive Surgery · Original study.

    Open original source ↗
  2. S2Bourin P et al. / IFATS–ISCT.

    Stromal cells from the adipose tissue-derived stromal vascular fraction and culture expanded adipose tissue-derived stromal/stem cells. 2013. Cytotherapy · Consensus statement.

    Open original source ↗
  3. S3Nazaroff J et al..

    Reporting in clinical studies on platelet-rich plasma therapy among all medical specialties. 2021. Systematic review.

    Open original source ↗
  4. S4Gutierrez-Ontalvilla P et al..

    The Effect of Lipofilling and Platelet-Rich Plasma on Patients with Moderate–Severe Vulvar Lichen Sclerosus. 2022. Aesthetic Plastic Surgery · Randomised pilot study.

    Open original source ↗
  5. S5Bano N et al..

    Nano Fat Therapy and Platelet Rich Plasma Versus Nano Fat Therapy Alone on Burn Scar. 2025. Annals of Burns and Fire Disasters · Comparative study.

    Open original source ↗
  6. S6Al-Sabri G et al..

    The Effectiveness of Nanofat in the Management of Skin Scars. 2025. Systematic review (heterogeneous procedures).

    Open original source ↗
  7. S7Duffy A et al..

    Topical platelet-rich plasma as a possible treatment for olfactory dysfunction—A randomized controlled trial. 2024. Randomised trial of PRP alone.

    Open original source ↗
  8. S8La Padula S et al..

    Effects of Nanofat and PRP on Type I Collagen Production in Striae Distensae. 2024 online; 2025 issue. Aesthetic Plastic Surgery · Randomised study.

    Open original source ↗
  9. S9Kuo P-J, Lin P-C, Hsieh C-H.

    Autologous Nanofat Injection for Cutaneous Scars: A PRISMA 2020 Systematic Review of Clinical Outcomes and Certainty of Evidence. 26.10.2026. Therapeutics and Clinical Risk Management · GRADE review.

    Open original source ↗
  10. S10Retraction notice.

    Retraction concerning a study of nanofat and adjunctive procedures. 11.2025. Retraction; not used as efficacy evidence.

    Open original source ↗
Editorial note: For qualified healthcare professionals. Status November 2026. Not legal advice or a recommendation to treat. No conclusion on the legality of any particular preparation or application. The cited studies address different products and indications.
Product added to wishlist
Product added to compare.
group_work Cookie consent